ArticleBiological procedures online2025
Arsenic Sulfide Induces Apoptosis in Myelodysplastic Neoplasm Cells Through the Suppression of ABI2.
Article in Biological procedures online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMyelodysplastic neoplasms (MDS) are a category of myeloid malignancies that can progress to acute myeloid leukemia (AML). Arsenic sulfide (As₂S₂) has demonstrated efficacy in the treatment of MDS. However, further investigation is required to elucidate its specific therapeutic targets.
objectiveTo examine the influence of ABI2 on MDS and clarify the regulatory role of As₂S₂ on ABI2 within the therapeutic framework of MDS.
methodsTo explore ABI2's role in the expression and prognosis of patients with hematological malignancies, RNA interference was used to reduce ABI2 expression in SKM-1, K562 and MDS-L cell lines. The therapeutic efficacy of As₂S₂ and its regulatory impact on ABI2 were evaluated both in vitro and in vivo.
resultsABI2 was found to be overexpressed in the peripheral blood of patients with MDS and AML, which was significantly associated with decreased survival rates in AML patients. Inhibition of ABI2 decreased the proliferation and increased the apoptosis of SKM-1, K562 and MDS-L cells. As₂S₂ also inhibited cell proliferation and induced apoptosis in these cells, but its efficacy diminished significantly with ABI2 silencing. Additionally, As₂S₂ showed therapeutic benefits in NHD13 mice by downregulating bone marrow ABI2 expression.
conclusionThe collective findings suggest that ABI2 is significantly overexpressed in MDS and AML, and its expression was correlated with unfavorable prognostic outcomes. Furthermore, As₂S₂ demonstrates therapeutic efficacy in MDS by modulating the expression levels of ABI2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.